Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Celularity Inc (CELUW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: CELUW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.76 | 52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.77% | Operating Margin (TTM) -52.25% |
Management Effectiveness
Return on Assets (TTM) -17.42% | Return on Equity (TTM) -232.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11684589 |
Shares Outstanding - | Shares Floating 11684589 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016, focusing on developing cellular medicines from placental-derived cells. It went public through a SPAC merger in 2021. The company aims to address unmet needs in immuno-oncology, infectious diseases, and degenerative diseases.
Core Business Areas
- Allogeneic Cell Therapy: Developing off-the-shelf cell therapies derived from placental cells for various diseases including cancer and autoimmune disorders.
- Biologics: Creating products such as bio-sourcing services to customers in the Biotech and Pharmaceuticals industries.
Leadership and Structure
The leadership team includes Robert Hariri, MD, PhD as Founder, Chairman and Chief Executive Officer. The company is structured with departments for research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- CYNK-001: An allogeneic natural killer (NK) cell therapy targeting hematologic malignancies and solid tumors. Market share data is not readily available. Competitors include Fate Therapeutics (FATE), Nkarta (NKTX), and other companies developing NK cell therapies.
- PDA-002: A placental-derived adherent cell therapy for Crohn's disease. Market share data is not readily available. Competitors include Takeda (ENTYVIO), AbbVie (HUMIRA).
- BioSourcing Services: Supply of high-quality human cells and tissues to customers in the Biotech and Pharmaceuticals industries. Market share data is not readily available. Competitors include Lonza, Charles River Laboratories.
Market Dynamics
Industry Overview
The cell therapy market is experiencing significant growth, driven by advancements in biotechnology and increasing demand for personalized medicine. Immuno-oncology is a key growth area.
Positioning
Celularity is positioned as a player in the allogeneic cell therapy market, with a focus on placental-derived cells. Its competitive advantage lies in its proprietary technology and access to placental tissue.
Total Addressable Market (TAM)
The global cell therapy market is estimated to reach billions of dollars. Celularity is positioned to capture a portion of this market with its innovative therapies, targeting specific disease areas. TAM estimated to be 75 Billion USD.
Upturn SWOT Analysis
Strengths
- Proprietary placental cell technology
- Diverse pipeline of cell therapies
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited commercialized products
- High cash burn rate
- Dependence on clinical trial success
- Uncertain regulatory landscape
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in cell therapy manufacturing
- Positive clinical trial results
Threats
- Competition from established biotech companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- FATE
- NKTX
- CRIS
Competitive Landscape
Celularity faces competition from established biotech companies and other cell therapy developers. Its advantages lie in its placental cell technology, but it needs to overcome the challenges of clinical development and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the development stage.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and successful commercialization of its products. Analyst estimates vary widely, reflecting the uncertainty.
Recent Initiatives: Recent initiatives include advancing clinical trials for its cell therapy candidates and seeking partnerships to expand its reach.
Summary
Celularity is a biotech company focused on placental-derived cell therapies with a diverse pipeline. While its proprietary technology is a strength, it faces challenges related to clinical development and commercialization. The company's high cash burn rate and dependence on clinical trial success are key risks to watch out for. If clinical trials are positive, this could change the company narrative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company Website
Disclaimers:
This analysis is based on available information and represents a snapshot in time. Investment decisions should be based on thorough research and consultation with a financial advisor. Market Share % are estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-07-19 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.